These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 28748465)
1. Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel. Houtmann S; Schombert B; Sanson C; Partiseti M; Bohme GA Methods Mol Biol; 2017; 1641():187-199. PubMed ID: 28748465 [TBL] [Abstract][Full Text] [Related]
2. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. Guo L; Guthrie H J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217 [TBL] [Abstract][Full Text] [Related]
3. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system. Guthrie H; Livingston FS; Gubler U; Garippa R J Biomol Screen; 2005 Dec; 10(8):832-40. PubMed ID: 16234341 [TBL] [Abstract][Full Text] [Related]
4. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel. Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686 [TBL] [Abstract][Full Text] [Related]
5. Observations on conducting whole-cell patch clamping of the hERG cardiac K Kang J; Luo Y; Searles M; Rampe D J Appl Toxicol; 2017 Apr; 37(4):445-453. PubMed ID: 27553911 [TBL] [Abstract][Full Text] [Related]
6. Improved throughput of PatchXpress hERG assay using intracellular potassium fluoride. Zeng H; Penniman JR; Kinose F; Kim D; Trepakova ES; Malik MG; Dech SJ; Balasubramanian B; Salata JJ Assay Drug Dev Technol; 2008 Apr; 6(2):235-41. PubMed ID: 18471077 [TBL] [Abstract][Full Text] [Related]
7. A history of the role of the hERG channel in cardiac risk assessment. Rampe D; Brown AM J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024 [TBL] [Abstract][Full Text] [Related]
8. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG. Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595 [TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel. Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182 [TBL] [Abstract][Full Text] [Related]
10. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp. Haraguchi Y; Ohtsuki A; Oka T; Shimizu T BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227 [TBL] [Abstract][Full Text] [Related]
11. Manual whole-cell patch-clamping of the HERG cardiac K+ channel. Chen XL; Kang J; Rampe D Methods Mol Biol; 2011; 691():151-63. PubMed ID: 20972752 [TBL] [Abstract][Full Text] [Related]
12. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology. Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629 [TBL] [Abstract][Full Text] [Related]
13. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732 [TBL] [Abstract][Full Text] [Related]
14. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500 [TBL] [Abstract][Full Text] [Related]
15. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530 [TBL] [Abstract][Full Text] [Related]
16. Recording hERG potassium currents and assessing the effects of compounds using the whole-cell patch-clamp technique. Helliwell RM Methods Mol Biol; 2008; 491():279-95. PubMed ID: 18998101 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118 [TBL] [Abstract][Full Text] [Related]
18. Effects of common antitussive drugs on the hERG potassium channel current. Deisemann H; Ahrens N; Schlobohm I; Kirchhoff C; Netzer R; Möller C J Cardiovasc Pharmacol; 2008 Dec; 52(6):494-9. PubMed ID: 19034038 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764 [TBL] [Abstract][Full Text] [Related]
20. Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Tao H; Santa Ana D; Guia A; Huang M; Ligutti J; Walker G; Sithiphong K; Chan F; Guoliang T; Zozulya Z; Saya S; Phimmachack R; Sie C; Yuan J; Wu L; Xu J; Ghetti A Assay Drug Dev Technol; 2004 Oct; 2(5):497-506. PubMed ID: 15671647 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]